{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T04:14:36Z","timestamp":1746072876515,"version":"3.40.4"},"reference-count":5,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.oret.2025.01.013","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:30:24Z","timestamp":1740123024000},"page":"e39-e40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Cai et\u00a0al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an\u00a0observational health\u00a0data\u00a0sciences\u00a0and informatics\u00a0network study (Ophthalmol Retina.\u00a02024;8:733-743)"],"prefix":"10.1016","volume":"9","author":[{"given":"Flora","family":"Lum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2025.01.013_bib1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.oret.2024.03.014","article-title":"Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an observational health data sciences and informatics network study","volume":"8","author":"Cai","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.01.013_bib2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jamaophthalmol.2019.1971","article-title":"Analysis of anti-vascular endothelial growth factor injection claims data in US Medicare Part B beneficiaries from 2012 to 2015","volume":"137","author":"Berkowitz","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.013_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/jrsm.1390","article-title":"Examining overlap of included studies in meta-reviews: guidance for using the corrected covered area index","volume":"11","author":"Hennessy","year":"2020","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.oret.2025.01.013_bib4","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/ije\/dyy120","article-title":"Evaluating large-scale propensity score performance through real-world and synthetic data experiments","volume":"47","author":"Tian","year":"2018","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.oret.2025.01.013_bib5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jclinepi.2022.09.009","article-title":"Logistic regression frequently outperformed propensity score methods, especially for large datasets: a simulation study","volume":"152","author":"Wilkinson","year":"2022","journal-title":"J\u00a0Clin Epidemiol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025000156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025000156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T07:30:19Z","timestamp":1745998219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025000156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2468653025000156"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.01.013","relation":{},"ISSN":["2468-6530"],"issn-type":[{"type":"print","value":"2468-6530"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Cai et\u00a0al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an\u00a0observational health\u00a0data\u00a0sciences\u00a0and informatics\u00a0network study (Ophthalmol Retina.\u00a02024;8:733-743)","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2024.03.014","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}